- Home
- GRVY vs EDIT Comparison
GRVY vs EDIT Comparison
Compare GRVY & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | EDIT |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.7M | 432.8M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GRVY | EDIT |
|---|---|---|
| Price | $61.75 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 33.0K | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $54.54 | $1.66 |
| 52 Week High | $74.75 | $4.54 |
Technical Indicators
Market Signals| Indicator | GRVY | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 37.19 |
| Support Level | $59.87 | $2.36 |
| Resistance Level | $63.94 | $2.73 |
| Average True Range (ATR) | 1.87 | 0.21 |
| MACD | -0.40 | -0.08 |
| Stochastic Oscillator | 31.36 | 2.06 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. The gaming products of the company include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation. Geographically, it derives maximum revenue from Taiwan.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.